SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received ...

The incidence of invasive breast cancer after conservative treatment for ductal carcinoma in situ (DCIS) decreased by more than 50% over the past 30 years, data from a Dutch cancer registry showed.

Please provide your email address to receive an email when new articles are posted on . Results showed a lower 2-year cumulative rate of invasive ipsilateral breast cancer among patients assigned ...

SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended treatment, the randomized COMET ...

SAN ANTONIO – Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ...

Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study A ...

LAGUNA HILLS, Calif., March 14, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics, has unveiled data from an analysis of over 700 early-stage invasive breast ...

References: 1.  Thailand Food and Drug Administration. Public Pharmaceutical Regulatory Information: NERLYNX. Available at: ...